ODE IV Director Murphy will work on pediatric labeling initiative when she joins FDA March 1.

Executive Summary

ODE IV DIRECTOR MURPHY WILL FOCUS ON PEDIATRIC LABELING initiatives and development of a list of drugs that require pediatric clinical data as specified in the FDA Modernization Act. Dianne Murphy, MD, will assume directorship of the Center for Drug Evaluation and Research's Office of Drug Evaluation IV, which comprises the divisions of anti-viral and anti-infective drugs, on March 1. Murphy is the chief of general pediatrics at the University of Florida Health Science Center in Jacksonville.